title: Role of Fc Receptors as a therapeutic target.
abstract: It has been forty years since the discovery of Fc Receptors and their function. Fc Receptors include the IgG receptors (FcgammaR), high-affinity IgE receptor (FcepsilonRI), IgA and IgA/IgM receptors, and neonatal Fc receptor for IgG (FcRn). In particular, the FcgammaRs have been well known to play an important role in many biologic processes including those associated with the response to infection and cancer as well as in the pathogenesis of immune-mediated diseases. Both positive and negative regulatory function has ascribed to Fc receptors and FcgammaRs in particular which serve to establish a threshold for immune cell activation. In other cases, Fc receptors such as FcRn possess a novel structure and function by playing a major role in the transport of IgG across polarized epithelial barriers at mucosal surfaces and in the regulation of IgG half-life. These diverse functions highlight the potential effectiveness of targeting Fc receptors for therapeutic purposes. This review summarizes new information available in the therapeutic applications of this biology.
authors.affiliation: Department of Gastroenterology, Kobe University School of Medicine, Kobe, Hyogo, Japan.
authors.forename: Atsuhiro
authors.initials: A
authors.lastname: Masuda
authors.forename: Masaru
authors.initials: M
authors.lastname: Yoshida
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Shiomi
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Morita
authors.forename: Hiromu
authors.initials: H
authors.lastname: Kutsumi
authors.forename: Hideto
authors.initials: H
authors.lastname: Inokuchi
authors.forename: Shigeto
authors.initials: S
authors.lastname: Mizuno
authors.forename: Akira
authors.initials: A
authors.lastname: Nakamura
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Takai
authors.forename: Richard S
authors.initials: RS
authors.lastname: Blumberg
authors.forename: Takeshi
authors.initials: T
authors.lastname: Azuma
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000920:Antibody-Dependent Cell Cytotoxicity; D017951:Antigen Presentation; D001327:Autoimmune Diseases / Q000276:immunology / Q000628:therapy; D004358:Drug Therapy / Q000639:trends; D025461:Feedback, Physiological / Q000276:immunology*; D015395:Histocompatibility Antigens Class I / Q000737:chemistry / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D006801:Humans; D007239:Infections / Q000276:immunology / Q000628:therapy; D008213:Lymphocyte Activation; D008223:Lymphoma / Q000276:immunology / Q000628:therapy; D021381:Protein Transport; D011961:Receptors, Fc / Q000737:chemistry / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D017455:Receptors, IgE / Q000737:chemistry / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D017452:Receptors, IgG / Q000737:chemistry / Q000235:genetics / Q000276:immunology* / Q000378:metabolism
chemical_list: D000911:Antibodies, Monoclonal; D015395:Histocompatibility Antigens Class I; D011961:Receptors, Fc; D017455:Receptors, IgE; D017452:Receptors, IgG; C100688:Fc receptor, neonatal